According to Zhitong Finance App, Zhaoke Ophthalmology-B (06622.HK) announced that on July 13, 2026, the company's innovative drug YUVEZZI™ (2.75% cabacholine and 0.1% bromonidine tartrate eye drops) has been approved by the Macao Special Administrative Region Government Drug Administration for the treatment of presbyopia.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.